Recent increased understanding of the underlying molecular biology of RCC has established the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways as relevant therapeutic targets [5]. Here, MTOR is linked to renal cell carcinoma.